Checking Measles Vaccine Protection in Young Children With Sickle Cell Disease
Checks whether measles vaccines protect infants and young children with sickle cell disease.
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Cincinnati, United StatesSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
- Status
- Recruiting
- People taking part
- 130 people, planned
- Started
- 13 Mar 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 2 groups
- Record updated
- 21 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with confirmed sickle cell disease who are due for measles vaccination within 3 months. It checks whether the vaccine gives them enough protection.
- Age
- From 6 months to 6 years.
- Sex
- All sexes can join.
- Disease stage
- Confirmed sickle cell disease.
- Earlier treatment
- Due for measles vaccination within 3 months, as set by national guidelines.
Main reasons for not taking part
- Known primary immunodeficiency syndrome that would prevent live virus vaccines
- Cancer that would prevent live virus vaccines
- AIDS that would prevent live virus vaccines
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Participants with confirmed Sickle Cell Disease
- Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines
- Willing and able to provide informed consent
- Ability to comply with study related evaluations and follow-up visits
Who cannot take part
- Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines
Where in United States
Also in 2 other countries, 2 sites
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: MacKenzie TassetTaking people
About the trial
What the trial wants to find out
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
The 2 groups in the trial
- Second Measles Vaccine (MV2)
Participants who receive second measles vaccine.
- First Measles Vaccine (MV1)
Participants who obtain the first measles vaccine.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
- Plain-language title
- Checking Measles Vaccine Protection in Young Children With Sickle Cell DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 21 January 2026